TP53 and myelodysplastic syndrome: Among pre-treatment IPSS-R low-risk MDS, 9/37 cases (24%) had >1% of p53+ elements (ranging from 1% to 5%) while in the high-risk group, the number of cases was higher (11/20, 55%), with p53+ elements ranging from 1% up to 40%.